Cannabinoid and psychedelics biotech Incannex Healthcare (ASX: IHL) has completed dosing of participants in its phase two proof-of-concept clinical trial of IHL-42X for the treatment of obstructive sleep apnoea. The company has also commenced preparation of a pre-investigational new drug (pre-IND) meeting package, targeting a meeting with the US Food and Drug Administration (FDA) in […]
The post Incannex Healthcare completes dosing in phase two proof-of-concept trial of IHL-42X for obstructive sleep apnoea appeared first on Small Caps.
from Small Caps https://ift.tt/3miLvZa
Post a Comment